Gultekin SH, Rosenfeld MR, Voltz R et al. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 2000;123:1481–94.

## Autoimmune limbic encephalitis

Editor – We read with interest the recent article by Derry *et al* (*Clin Med* October 2011 pp 479–82) concerning limbic encephalitis (LE). There are important additional issues leading on from this succinct article that may be useful to the general physician when considering a LE diagnosis.

As reflected in the article, the diagnosis of autoimmune encephalitis (AE) and, more specifically, LE is a difficult one with no causative agent identified in up to two-thirds of encephalitic patients referred to specialist centres.<sup>1</sup>

As mentioned in the article, recent work has indicated potassium channels are not the antigenic target in LE and it is in fact Anti-LGI1 (Leucine-rich glioma inactivate 1).<sup>2,3</sup> In addition, other studies suggest that another auto-antigen 'CASPR2 - contactin-associated protein-like 2' (expressed in hippocampal neurons) is associated with illnesses previously attributed to anti-VGKC antibodies such as drug-refractory epilepsy, encephalitis, peripheral nerve dysfunction, or a combination of both: Morvan syndrome or neuromyotonia.<sup>4–7</sup> Therefore, the term 'anti-VGKC' encephalitis is no longer in routine use.

The authors rightly illustrate the cardinal symptoms of LE as being severe short-term memory impairment with psychiatric symptoms such as personality change, depression, anxiety, hallucinations, confusion, and complex partial (often temporal) and generalised seizures.<sup>8,9</sup> It must be recalled that auto-antibodies may take some weeks to process and often LE treatment will have to be initiated prior to definitive diagnosis. With this in mind, there are other clinical features that may assist in pointing the clinician towards the diagnosis of LE. Features classically associated with anti-LGI1 encephalitis include faciobrachial tonic seizures<sup>7</sup> and, in 40% of patients, myoclonus.2 With regards to initial blood tests, hyponatraemia is a patients both with and without underlying malignancy, indicating that it is not purely a paraneoplastic phenomenon.<sup>10</sup> Autonomic instability is also described.

Once LE has been identified, it is essential to exclude paraneoplastic aetiology such as anti-Hu or anti-Ma2 associated LE as tumour treatment and, if possible, removal is associated with better outcomes than immunomodulatory therapy alone.<sup>3</sup> It is important to note that the encephalitic presentation will precede the identification of the neoplasm in up to three quarters of patients.<sup>9,11,12</sup>

Thankfully, as the article points out, non-paraneoplastic LE is associated with good outcomes if recognised early and treated aggressively. However, the clinician must be alert to the fact that residual neurological deficits may be subtle, difficult to elicit and, in some cases, sufficient to preclude the patient's return to work.

It is clear that the earlier AE or LE is diagnosed and therapy started, the better the outcome. We recently published an AE review containing a clinical algorithm for work-up, diagnosis, and treatment of autoimmune encephalitis<sup>13</sup> that – in conjunction with important articles such as Derry *et al*'s – we hope will assist the neurologist and generalist alike in early AE diagnosis and treatment.

T WINGFIELD<sup>1</sup> C MCHUGH<sup>2,3</sup> A VAS<sup>1</sup> A RICHARDSON<sup>2</sup> E WILKINS<sup>1</sup> A BONINGTON<sup>1</sup> A VARMA<sup>2,3</sup>

<sup>1</sup>The Monsall Unit, Department of Infectious Diseases and Tropical Medicine, North Manchester General Hospital <sup>2</sup>Department of Neurology, Salford Royal Hospital, Manchester <sup>3</sup>Department of Neurology, North Manchester General Hospital

## References

1 Glaser CA, Honarmand S, Anderson LJ, Schnurr DP et al. Beyond viruses: clinical profiles and etiologies associated with encephalitis. Clin Infect Dis

- Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. *Lancet Neurol* 2010;9:776–85.
- 3 Irani S, Lang B. Auto-antibody mediated disorders of the central nervous system. *Autoimmunity* 2008;41:55–65.
- 4 Ligouri R, Vincent A, Clover L *et al.*Morvan's syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. *Brain* 2001;124:2416–26.
- 5 Barber PA, Anderson NE, Vincent A. Morvan's syndrome associated with voltage-gated postassium channel antibodies. *Neurology* 2000;54:771–2.
- 6 Lancaster E, Huijbers MG, Bar V et al. Investigations of CASPR2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol 2010;69:303–11.
- 7 Irani SR, Michell AW, Lang B et al. Faciobrachial dystonic seizures precede LGI1 antibody limbic encephalitis. Ann Neurol 2011;69:892–900.
- 8 Lawn ND, Westmoreland BF, Kiely MJ et al. Clinical, magnetic resonance imaging, and electroencephalographic findings in paraneoplastic limbic encephalitis. Mayo Clin Proc 2003;78:1363–8.
- 9 Gultekin SH, Rosenfield MR, Voltz R *et al.* Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. *Brain* 2000;123:1481–94.
- 10 Vernino S, Geschwind M, Boeve B. Autoimmune encephalopathies. *Neurologist* 2007;13:140–7.
- 11 Daniel SE, Love S, Scaravilli F *et al.* Encephalomyeloneuropathy in the absence of a detectable neoplasm. Clinical and post-mortem findings in three cases. *Acta Neuropathol* 1985;66: 311–17.
- 12 Bien CG, Schulze-Bonhage A, Deckert M *et al.* Limbic encephalitis not associated with neoplasm as a cause for temporal lobe epilepsy. *Neurology* 2000;55:1823–8.
- 13 Wingfield T, McHugh C, Vas A et al. Autoimmune encephalitis: a case series and comprehensive review of the literature. QJM 2011;104:921–31.

## The changing landscape of anticoagulation and atrial fibrillation

Editor – We read with great interest the article by Breen and Hunt which presented an overview of the new oral anticoagulants (*Clin Med* October 2011 pp 497–9). We wish to highlight three new studies published since their review was